How big is Twist Bioscience Corp.?

As of Jun 18, Twist Bioscience Corp. has a market capitalization of $2.03 billion, with net sales of $347.67 million and a net profit of -$191.15 million over the last four quarters. The company reported shareholder's funds of $472.69 million and total assets of $614.32 million as of Sep 24.

Market Cap: As of Jun 18, Twist Bioscience Corp. has a market capitalization of 2,032.36 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Twist Bioscience Corp. reported net sales of 347.67 million and a net profit of -191.15 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 472.69 million and total assets of 614.32 million.

What does Twist Bioscience Corp. do?

Twist Bioscience Corporation is a synthetic biology company specializing in DNA synthesis, with recent net sales of $93 million and a net loss of $39 million. It has a market cap of approximately $2.03 billion and operates within the Pharmaceuticals & Biotechnology industry.

Overview:<BR>Twist Bioscience Corporation is a synthetic biology company that develops a disruptive DNA synthesis platform, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 93 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -39 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,032.36 Million (Small Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.55 <BR>Return on Equity: -33.22% <BR>Price to Book: 4.62 <BR><BR>Contact Details:<BR>Address: 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA: 94080 <BR>Tel: 1 408 4100105 <BR>Fax: 1 302 5313150 <BR>Website: https://www.twistbioscience.com/

Should I buy, sell or hold Twist Bioscience Corp.?

Who are in the management team of Twist Bioscience Corp.?

As of March 2022, the management team of Twist Bioscience Corp. includes Ms. Emily Leproust as Chairman, President, and CEO, and Dr. William Banyai as Senior VP of Research and Development. The Board features independent directors, including Mr. Robert Chess as Lead Independent Director.

As of March 2022, the management team of Twist Bioscience Corp. includes:<BR><BR>- Ms. Emily Leproust, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Dr. William Banyai, who is the Senior Vice President of Research and Development, General Manager of Data Storage, and a Director.<BR><BR>Additionally, the Board of Directors consists of several independent directors, including Mr. Robert Chess as the Lead Independent Director, and Mr. Nicolas Barthelemy, Mr. Nelson Chan, Mr. Keith Crandell, and Mr. Jan Johannessen as Independent Directors.

Is Twist Bioscience Corp. technically bullish or bearish?

As of October 3, 2025, Twist Bioscience Corp. has a mildly bearish trend overall, with mixed technical indicators, having outperformed the S&P 500 in the short term but significantly underperformed year-to-date.

As of 3 October 2025, the technical trend for Twist Bioscience Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators showing mixed signals. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and the KST indicates a bearish trend on the weekly and mildly bearish on the monthly. Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, returning 17.96% and 23.64% respectively, but has significantly underperformed over longer periods, with a year-to-date return of -31.46% compared to the S&P 500's 14.18%.